Targeted rapid testing for SARS-CoV-2 in the emergency department is associated with large reductions in uninfected patient exposure time.

Autor: Hinson, J.S., Rothman, R.E., Carroll, K., Mostafa, H.H., Ghobadi, K., Smith, A., Martinez, D., Shaw-Saliba, K., Klein, E., Levin, S.
Zdroj: Journal of Hospital Infection; Jan2021, Vol. 107, p35-39, 5p
Abstrakt: Opportunity exists to decrease healthcare-related exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), preserve infection control resources, and increase care capacity by reducing the time to diagnosis of coronavirus disease 2019 (COVID-19). A retrospective cohort analysis was undertaken to measure the effect of targeted rapid molecular testing for SARS-CoV-2 on these outcomes. In comparison with standard platform testing, rapid testing was associated with a 65.6% reduction (12.6 h) in the median time to removal from the isolation cohort for patients with negative diagnostic results. This translated to an increase in COVID-19 treatment capacity of 3028 bed-hours and 7500 fewer patient interactions that required the use of personal protective equipment per week. [ABSTRACT FROM AUTHOR]
Databáze: Supplemental Index
Externí odkaz: